"I am excited to begin this collaboration with NeoStem," said Dr. Bluestone. "Their in-house expertise in development and manufacturing will serve as a complement to my team at UCSF and, through this partnership, I look forward to building on a strong existing foundation, moving these products through clinical development to treat diseases which have long been a focus of my own clinical research.""NeoStem has core expertise in the development and conduct of cell therapy based trials," said Dr. Andrew L. Pecora, Chief Medical Officer of NeoStem. "This collaboration accelerates the development of our immunomodulatory therapeutic portfolio, enabling the initiation of a Phase 2 trial in type 1diabetes and a Phase 1b/2a trial in steroid resistant asthma. This development significantly diversifies and augments NeoStem's cell therapy pipeline, which includes a Phase 2 cardiovascular clinical trial which is expected to complete enrollment in 2013."
NeoStem Advances Autoimmune Platform Through UCSF Collaboration
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.